• Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

    Source: Nasdaq GlobeNewswire / 18 Jan 2024 12:00:00   America/New_York

    N/A
Share on,